PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT.
In her presentation, Dikla Czaczkes Akselbrad, Polypid’s EVP and CFO will provide corporate highlights and discuss recent developments.
PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scientific Officer Dr. Noam Emanuel, will deliver a virtual presentation at the first World Association against Infection in Orthopaedics and Trauma (WAIOT) Congress on August 28, 2021.
The virtual presentation will be a part of the Septic Non-Union and Bone Loss Management session. The presentation details can be found below:
Location: Room 3
Lecture Number: 0 41
Time: 16:11 – 16:16 CEST
Improved Healing of Gustilo Type IIIA and IIIB Open Long Bone Fractures Treated with Local Biodegradable Prolonged Release Antibiotic Formulated Bone Graft During the First Surgical Intervention Post-Surgery: A Prospective, Randomized Clinical Trial
Dr. Noam Emanuel, PolyPid
WAIOT is the first and the largest worldwide scientific association, focused on bone, joints, biofilms- and implant-related infections. The event will be attended by 1,700 members coming together virtually from 101 countries.
PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief Financial Officer Dikla Czaczkes Akselbrad will present a corporate overview at the Investor Summit Virtual Conference being held August 17 – 18, 2021.
Ms. Czaczkes Akselbrad will deliver her corporate presentation on August 18 at 9:30am ET.
Management will be available for one-on-one meetings to be held throughout the conference.
Investors can register here: Q3 Investor Summit Registration
PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2021 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
The Raymond James Human Health Innovation Conference presentation will be webcast live and archived for 1 year on PolyPid's Investor Relations website at https://investors.polypid.com/events-and-presentations/events.
PETAH TIKVA, Israel,